Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 311 results for breast cancer

  1. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  2. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

  3. Studies exploring the effectiveness of bevacizumab in people previously treated with a taxane and its effects on health-related quality of life.

    combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012 Other

  4. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101 Date issued

  5. Cough (acute): antimicrobial prescribing (NG120)

    This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.

  6. Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.

    combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other

  7. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

  8. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

  9. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

  10. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued

  11. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.

  12. Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

  13. Menopause (QS143)

    This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.

  14. Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)

    Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.